/

Società

NM

Non verificato

NMD Pharma

Di cosa scriviamo

Annunci EconomiciBiotecnologiaPubblicità/Marketing/Media/Comunicazione

13 comunicati stampa

Guarda tutti i comunicati

22/07/2026

Biotecnologia

Pubblicità/Marketing/Media/Comunicazione

NMD Pharma Announces Publication Identifying Neuromuscular Junction Transmission Failure as a Novel Contributor to Age-Related Muscle Weakness

Fonte

Emittente

1.00

0

16/06/2026

Biotecnologia

Pubblicità/Marketing/Media/Comunicazione

SYNAPSE-CMT Phase 2a Clinical Study Data Presented in Late-Breaking Oral Presentation at 2026 PNS Annual Meeting

Fonte

Emittente

1.00

0

10/03/2026

Biotecnologia

Annunci Economici

Pubblicità/Marketing/Media/Comunicazione

NMD Pharma late breaking oral presentation at the MDA Conference with top-line safety and efficacy data from SYNAPSE-CMT, an exploratory Phase 2a clinical study of ignaseclant in Charcot-Marie-Tooth disease Types 1 & 2

Fonte

Emittente

1.00

0

11/02/2026

Biotecnologia

Pubblicità/Marketing/Media/Comunicazione

Annunci Economici

NMD Pharma results from Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2 selected for late-breaking oral presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Fonte

Emittente

1.00

0

02/02/2026

Biotecnologia

Annunci Economici

Pubblicità/Marketing/Media/Comunicazione

NMD Pharma announces topline results from its Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2

Fonte

Emittente

1.00

0

02/09/2025

Biotecnologia

Pubblicità/Marketing/Media/Comunicazione

Annunci Economici

NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer

Fonte

Emittente

1.00

0

12/05/2025

Biotecnologia

Pubblicità/Marketing/Media/Comunicazione

Annunci Economici

NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA International Conference on Myasthenia and Relate

Fonte

Emittente

1.00

0

24/03/2025

Biotecnologia

Annunci Economici

NMD Pharma presents preclinical data highlighting increased innervation of skeletal muscle with ClC-1 ion channel inhibition treatment in neuromuscular disease model

Fonte

Emittente

1.00

0

05/01/2025

Biotecnologia

Pubblicità/Marketing/Media/Comunicazione

Annunci Economici

NMD Pharma Announces FDA Orphan Drug Designation Granted to NMD670 for the Treatment of Patients with Charcot-Marie-Tooth Disease

Fonte

Emittente

1.00

0

18/12/2024

Biotecnologia

Annunci Economici

NMD Pharma Announces Publication of Phase 1 Clinical Trial Data Evaluating NMD670 in Healthy Volunteers in the Journal Clinical Pharmacology & Therapeutics

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0